GSK Signs T-Cell Manufacturing Deal

By Akia Thorpe -

October 8, 2018

GlaxoSmithKline (GSK) has signed a three-year clinical manufacturing agreement with Hitachi Chemical Advanced Therapeutics Solutions (HCATS), an Allendale, New Jersey-based contract development and manufacturing organization.

Under the agreement, HCATS will manufacture GSK’s specific peptide enhanced affinity receptor T-cell receptor therapy, an investigational cancer immunotherapy being developed by GSK and Adaptimmune, an Oxfordshire, UK-based T-cell therapy company, for US, Canadian, and European trials. The receptor is expressed across a variety of tumors, including sarcomas, melanoma, multiple myeloma, bladder cancer, non-small cell lung cancer, ovarian cancer, and gastro-intestinal cancers, according to information from HCATS.

HCATS is a US subsidiary of Hitachi Chemical Co., a global conglomerate with a franchise in life sciences, including regenerative medicine, that engages in contract manufacturing and development of cell-based cell and gene therapy products through its PCT Global Service Platform.

Source: Hitachi Chemical Advanced Therapeutics Solutions